TNFRSF17 and Miyoshi myopathy: Therefore, Sakemura et al. (63), developed a dual-targeting CAR-T cell strategy, which targets both bone marrow CAFs (via SLAMF7 or Fibroblast activation protein/FAP) and MM cells (via BCMA).